Mammogram most effective 12 months after radiation treatment

November 25, 2008

Breast cancer patients who receive breast-conserving therapy and radiation do not need a follow-up mammogram until 12 months after radiation, despite current American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines that recommend follow-up mammograms at between six and 12 months after radiation, according to a November 15 study in the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.

According to the American Cancer Society, more than 182,000 women will be diagnosed with breast cancer in 2008, and many of these women will choose to undergo a lumpectomy and radiation therapy as their course of treatment, which has been shown to produce similar survival outcomes to a mastectomy. Mammography has been established as a crucial part of post-treatment surveillance for patients undergoing breast-conserving therapy, but the optimal timing of the initial mammogram is not clear.

Researchers at the University of California, Los Angeles, School of Medicine, Department of Radiation Oncology, Department of Pathology, and Department of Radiology and at the University of California, San Diego, School of Medicine sought to determine if the recommended timeframe for a post-treatment mammogram offers any benefit to patients.

The most recent NCCN guidelines proposes a follow-up mammogram six to 12 months after radiation, and according to 2006 guidelines, ASCO recommends a follow-up mammogram one year after the initial mammogram that leads to diagnosis, but no earlier than six months after radiation. Accounting for the time after the initial diagnostic mammogram to have a biopsy, surgery and radiation therapy, following the ASCO guidelines would likely result in mammograms being done six to nine months after the completion of radiation.

The researchers looked at 408 patients who were treated with breast-conserving therapy and radiation between 1995 and 2005 and who had follow-up mammograms at UCLA within one year after completing radiation. The median interval between radiation and the initial mammogram was 3.1 months. Only 10 patients had suspicious findings on their mammograms and of those only two were found to have recurrent cancer. Both of the cases were noninvasive ductal carcinomas.

The cost of a mammogram is about $115 and many women can experience moderate to severe pain during the procedure and high levels of anxiety during a needle biopsy. The authors determined that because only 0.49 recurrences were detected per 100 mammograms and only noninvasive ductal carcinoma was found, mammograms should not be performed until at least one year after radiation to avoid the medical and psychological costs associated with mammography.

"Omitting the initial post-radiotherapy examination may improve the psychological well-being of patients, especially for women who have already been shown to have breast cancer," Kevin Lin, M.D., lead author of the study and a radiation oncologist at Advanced Oncology Center in West Covina, Calif., said.
-end-
ASTRO is the largest radiation oncology society in the world, with 10,000 members who specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, biology and physics, the Society is dedicated to improving patient care through education, clinical practice, advancement of science and advocacy. For more information on ASTRO, visit www.astro.org. To learn about radiation therapy treatments, visit www.rtanswers.org.

American Society for Radiation Oncology

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.